Investment decisions in pharmaceutical R&D projects

Drug Discovery Today

Volumn 8, Issue 21, 2003, Pages 968-971

  Pandey, Mohan ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Corporate growth, market risk; Development; Drug Discovery; Net present value (NPV); Pharmaceutical Science; Real options methodology

Indexed keywords

DRUG;

COMPARATIVE STUDY; DECISION MAKING; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; INVESTMENT; METHODOLOGY; REVIEW;

EID: 0344011103     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02731-4     Document Type: Short Survey

References (9)

1. George, C. and Pearson, M.J. (2002) Riding the Pharma roller coaster. The McKinsey Quarterly, Number 4 ( http://www.mckinseyquarterly.com ).
2. Grabowski, H. Vernon, J and DiMasi J. (2002) Returns on R&D for 1990s New Drug Introductions, Center for the Study of Drug Development, Tufts University, March.
3. Sedlacek, H. Sapienza, A. Eid, V. (1996) Ways to Successful Strategies in Drug Research and Development, VCH.
4. Luehrman, T. A. (1998) Investment opportunities as Real Options, Harvard Business Review, July-August, 51-67.
5. Amram, M. and Kulatilaka, N. (2000) Strategy and shareholder value creation: the Real Options frontier, Journal of Applied Corporate Finance, Bank of America, Summer, 8-21.
6. Borissiouk, O. and Peli, J. (2002) Real Option Approach to R&D Project Valuation: Case Study at Serono International S. A. Thesis, University of Lausanne.
7. Shultis K. The dilemma of process development. Drug Discov. Today. 7:2002;850-853.
8. Sharpe, P. and Keelin, T. (1998) How SmithKline Beecham makes better resource-allocation decisions, Harvard Business Review, March-April, 3-10.
9. Neil, D. J. (2001) Setting milestone payments, Curr. Drug Discov. October, 33-35.